Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
about
Cabergoline for preventing ovarian hyperstimulation syndromeCabergoline for preventing ovarian hyperstimulation syndromeThiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitroOvarian hyperstimulation syndrome: pathophysiology, staging, prediction and preventionPrevention of Ovarian Hyperstimulation Syndrome: A ReviewCan dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysisThe effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSSVitamin D Decreases Serum VEGF Correlating with Clinical Improvement in Vitamin D-Deficient Women with PCOS: A Randomized Placebo-Controlled Trial.Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndromeOvarian hyperstimulation syndrome: pathophysiology and prevention.Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management.Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeysFollicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulationBlood and lymphatic vasculature in the ovary: development, function and disease.Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation.Dopamine agonists for preventing ovarian hyperstimulation syndrome.Treatment results of high dose cabergoline as an adjuvant therapy in six patients with established severe ovarian hyper stimulation syndrome.Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort studyThe pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndromeGnRH agonist vs. hCG for triggering of ovulation--differential effects on gene expression in human granulosa cells.Spontaneous bacterial peritonitis complicating ovarian hyperstimulation syndrome-related ascites.Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study.The effectiveness of cabergoline for the prevention of ovarian hyperstimulation syndrome.Ovarian hyperstimulation syndrome in a spontaneous pregnancy: A potential for missed-diagnosis.GnRH analogues in the prevention of ovarian hyperstimulation syndromeCombination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective studyA unique human chorionic gonadotropin antagonist suppresses ovarian hyperstimulation syndrome in rats.Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization.Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment.Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulationVEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status.Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.Dopamine agonists in prevention of ovarian hyperstimulation syndrome.Platelet-derived growth factor BB and DD and angiopoietin1 are altered in follicular fluid from polycystic ovary syndrome patients.Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume.Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles.
P2860
Q24203638-AA13ABB9-3C2B-4D4C-9300-E846E36BA1CEQ24234591-3A03D902-3CFE-43B2-8773-6266AEEA6CD6Q24608491-59A8DFEE-C2E0-4543-84DD-89049BA6CBDFQ26827593-0D6D63E6-F270-4CBF-B035-AAEB074691F9Q26828442-C0B09947-82A5-4B91-85F7-9345F6EEA868Q28278251-B37D60D4-80F6-4DB9-9B67-947B808AA0D6Q28831013-6D7BC385-92D5-4F06-BF6E-7AB2367169ADQ33616612-5D7A78CC-8DCD-4E55-94A6-D130D80D842DQ33624231-13EDAAD3-0083-44C0-8B40-70C71A6E4453Q33743560-24DFFF01-5A53-4582-9805-03E7C84B9D29Q33844520-499A41D3-463F-4CC5-B3F4-7EFD0A6B5B8CQ33883193-58A3C7D8-B1C1-4E46-A8F1-4C8AD040756BQ34116423-4F75BBF3-9A56-4943-AF8A-A1FB700E3801Q34375633-426DEC95-D787-4EE8-AC9C-11B17F7DD93DQ34428728-7805FAFC-8233-4DFA-8AD3-20BE9935BB97Q34546236-135D5E3C-7B26-4086-B6AA-DBCDCCBE5CF8Q34589550-3006AA59-CA59-45AE-84F2-5E467EBB4E57Q34641919-AB829164-3009-476F-9FDB-35C5647596AFQ35071420-23C001C4-6E12-4F50-BF66-2FBC279AD5A8Q35112937-D435C544-A637-4B3E-A6A2-5AF5CFFDA09BQ35580263-829FE6D9-272B-496D-A3FD-7D64C55C824AQ36112513-EAB0B609-0514-47B1-B3F9-D295EC4C859AQ36262733-E802870A-C1CC-4C5E-8A78-548E1FBFFA38Q36492269-100F5E3D-D2B8-487F-B641-2A0428915CBAQ36567091-C6C9A714-7DCB-4D17-A336-02355CA62471Q36876747-FAEACBD0-D0E8-4666-9984-EE55CB8DC9B5Q36957480-82A6AD3D-BB4E-4877-BC44-8DB5475A3919Q36966423-558F3E50-FEE2-49BC-9E9B-4390104676E5Q37281160-1209C849-B00F-4611-862B-7580974FCB18Q37362856-64CE9727-8FBF-4122-990B-8980F2ABCADBQ37372180-969FDD9B-3BF3-497F-A52E-2A791160C552Q37493521-E1769882-E7AB-4340-96A2-830043AF23B8Q37624402-635F9EAD-B35D-4469-BF4B-1BB03C49DD22Q38056538-3ACEE51C-8AB4-40CE-8653-51952EA2AEC1Q38237098-94232D61-64BE-44C1-B7CD-7738A6A192CAQ38989086-CEAE86A5-EB6D-4214-884D-2B7C3CA392E5Q39427213-584D80C8-C3BB-468A-9D11-44BDA5EC51C4Q41011753-3DA004E9-FD1F-4E09-9F1C-6B4B9A3F3732Q47142303-8E604524-3AE1-4706-9D13-A5BE20D13165Q47237836-B4C7F07D-D110-4D21-971B-177668A2BB34
P2860
Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Targeting the vascular endothe ...... ian hyperstimulation syndrome.
@ast
Targeting the vascular endothe ...... ian hyperstimulation syndrome.
@en
Targeting the vascular endothe ...... ian hyperstimulation syndrome.
@nl
type
label
Targeting the vascular endothe ...... ian hyperstimulation syndrome.
@ast
Targeting the vascular endothe ...... ian hyperstimulation syndrome.
@en
Targeting the vascular endothe ...... ian hyperstimulation syndrome.
@nl
prefLabel
Targeting the vascular endothe ...... ian hyperstimulation syndrome.
@ast
Targeting the vascular endothe ...... ian hyperstimulation syndrome.
@en
Targeting the vascular endothe ...... ian hyperstimulation syndrome.
@nl
P2093
P356
P1476
Targeting the vascular endothe ...... ian hyperstimulation syndrome.
@en
P2093
Juan Antonio García-Velasco
Raúl Gómez
Sérgio Reis Soares
P304
P356
10.1093/HUMUPD/DMN008
P577
2008-04-02T00:00:00Z